In 2018, Xu and colleagues conducted a relatively large‐scale retrospective study on the role of consolidative local ablative therapy (LAT) in oligometastatic (≤5 metastases) stage IV EGFRm NSCLC without progression after first‐line EGFR TKI treatment. This evidence concerns the gene EGFR and non-small cell lung carcinoma.